Cereno Scientific Achieves Key Clinical Milestone as First Patient Is Dosed in Global Phase IIb EPIMODE Trial of CS1 in PAH
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for rare cardiovascular and pulmonary diseases, today announced that the first patient has been randomized and dosed in EPIMODE, the Company’s global Phase IIb trial evaluating lead drug candidate CS1 in pulmonary arterial hypertension (PAH). First Patient In (FPI) marks the formal initiation of EPIMODE, with the trial now entering randomized treatment to further evaluate CS1’s efficacy and optimal dose, alongside safety and tolerability, while assessing its potential as a disease-modifying treatment for PAH.
The first patient has now completed screening, been randomized and received the first dose of study treatment, marking the transition into randomized treatment in EPIMODE. This significant milestone follows the activation of the first clinical site in August 2026 and the initiation of patient screening. In parallel, activation of additional specialist PAH centers continues across North America, Europe and South America to expand patient recruitment capacity.
“First patient randomization and dosing is an important milestone for EPIMODE. We have made substantial progress across the broader trial network, working closely with our CRO, investigators and clinical teams to prepare and activate additional specialist PAH centers. Regulatory, contractual and operational start-up activities are progressing across the planned countries in North America, Europe and South America. Our focus is on ensuring that participating sites are ready to identify potentially eligible patients in advance, where permitted, and move promptly into screening and randomization once operational and all necessary approvals are in place, progressively expanding recruitment capacity across the global network,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific.
A key step toward evaluating CS1’s disease-modifying potential
EPIMODE represents an important next step in the development of CS1, designed to evaluate whether the encouraging efficacy signals observed in the completed Phase IIa trial can be demonstrated in a larger, randomized and placebo-controlled setting.
PAH is a serious, progressive disease in which structural changes in the pulmonary blood vessels increase resistance to blood flow and place growing strain on the right side of the heart. Despite advances in treatment, significant medical needs remain. CS1 is being developed as an oral, once-daily treatment added to existing standard of care, with the potential to address underlying mechanisms driving disease progression, including vascular remodeling, fibrosis and inflammation.
In the completed Phase IIa trial, CS1 successfully met its primary endpoint demonstrating a favorable safety and tolerability profile together with exploratory efficacy signals, including improvements in right-heart function, functional class, risk score and patient quality of life, as well as early signs consistent with reverse vascular remodeling.
The subsequent 12-month Expanded Access Program (EAP) also met its primary objective of evaluating long-term safety and tolerability, confirming a favorable profile consistent with Phase IIa and extending the accumulated clinical treatment experience to approximately 15 months. Among the six patients who completed 12 months of treatment, the majority maintained or improved their clinical status across several clinically relevant functional and biomarker measures.
Together, these findings provide an encouraging clinical foundation for EPIMODE, which is designed to generate the controlled evidence needed to assess CS1’s efficacy, identify the optimal dose for continued development and further investigate its potential to modify the underlying disease process in PAH.
The trial’s primary endpoint is change in pulmonary vascular resistance (PVR) after nine months of treatment. PVR measures resistance to blood flow through the lungs and is a key measure of the vascular changes that place strain on the right side of the heart in PAH.
A distinguishing feature of EPIMODE is its two-stage design. Following the initial nine-month treatment period, patients are re-randomized, enabling the study to assess how treatment effects develop when CS1 treatment is continued, initiated or withdrawn. Patients initially assigned to placebo transition to active CS1 treatment during the second period.
This design is particularly relevant to evaluating CS1’s potential disease-modifying effects, as it may provide insights into the durability of treatment benefits and whether observed effects extend beyond an immediate treatment response. These insights, alongside the primary efficacy results, are intended to help define CS1’s differentiated therapeutic profile and inform its continued clinical development.
With randomized patient treatment now underway, Cereno Scientific has achieved a key operational milestone and is progressing toward the clinical data that will be central to evaluating CS1’s potential in PAH.
“Reaching first-patient dosing is a significant achievement for Cereno Scientific and our lead clinical development program. It marks the transition from extensive preparations to randomized patient treatment and delivers on an important near-term priority. We have built an encouraging clinical foundation for CS1 through Phase IIa and the subsequent Expanded Access Program, and EPIMODE is the next important step in evaluating that potential in a larger, controlled trial. What makes CS1 particularly promising is its potential to offer a different approach to PAH treatment by targeting the underlying mechanisms that drive disease progression. EPIMODE is designed not only to evaluate efficacy and identify the optimal dose, but also to investigate the durability of treatment effects and further assess CS1’s disease-modifying potential. Our focus is now on expanding patient recruitment and advancing toward the clinical results that will guide the next stage of CS1’s development. Ultimately, our goal is to develop a treatment that can extend and enhance the lives of people living with this serious and progressive disease,” said Sten R. Sörensen, CEO of Cereno Scientific.
Next milestones in EPIMODE
Cereno Scientific continues to advance site activation and recruitment preparations across the planned clinical sites in North America, Europe and South America. The Company expects up to 15 clinical sites to be activated by the end of 2026 and more than half of the planned global site network by the end of Q1 2027.
Based on the current site activation and recruitment plan, the Company continues to target completion of patient recruitment during 2027 and topline results in Q4 2028, subject to recruitment progress and securing the financing required to execute the trial as planned.